Codex DNA Clocks Q3 Sales Growth Of 75%; Acquires Eton Bioscience For $13M

  • Codex DNA Inc's DNAY Q3 revenues increased 75% Y/Y to $2.8 million. The total fell short of the consensus Wall Street estimate of $2.93 million.
  • Q3 was the first full quarter for Codex as a public company. The firm completed a $122.7 million initial public offering in June.
  • The EPS loss lowered to $(0.34) from $(0.89), but missing the consensus of $(0.28).
  • Codex DNA had $109.8 million in cash and equivalents.
  • Codex has acquired Eton Bioscience, a startup that offers synthetic biology products and services, including DNA sequencing and oligo synthesis, for $13 million in cash.
  • With the acquisition, Codex expects to accelerate the growth of its BioXp synthetic biology benchtop system.
  • Eton Bioscience, founded in 2003 and privately held, generated $5.1 million in revenues for the nine months ended September 30. 
  • Price Action: DNAY shares are up 0.11% at $9.29 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsM&ANewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!